Dr. Marco Gottardis describes his background in biopharma and why he’s excited to join LIfT as a Non-Executive Director
In this interview, Dr. Marco Gottardis outlines his background in cell therapy and biopharma, including his most recent role as VP of...
May 28, 2024
Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting
London, 24 May 2024  – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company about to start clinical trials for...
May 24, 2024
LIfT BioSciences Awarded Innovate UK Grant to Accelerate Product Development of New IMAN Cell Therapy Variants
Groundbreaking in vivo studies will be progressed to explore the impact of IMAN cell therapies in solid tumour and immunology models...
May 16, 2024
LIfT demonstrates how IMANs rapidly infiltrate tumours and recruit in other immune cells to destroy solid tumours together
LIfT’s CEO Alex Blyth detailed how Immuno-Modulatory Alpha Neutrophils (IMANs) outperform traditional neutrophils by rapidly infiltrating...
Apr 10, 2024
Dr. Bo Rode Hansen explains why he joined LIfT as a Non-Executive Director
We recently caught up with Dr. Bo Rode Hansen, a Non-Executive Director at LIfT, to find out what motivated him to join LIfT and why he...
Mar 5, 2024
